Business
Rasna Therapeutics Names Dr. Kunwar Shailubhai As New CEO
Rasna Therapeutics Names Dr. Kunwar Shailubhai As New CEO.
About this update from Actavia Life Sciences, Inc.
[{"type":"text","content":"\n \n Rasna Therapeutics, Inc. (OTCQX:RASP), is pleased to announce the \n appointment of Dr. Kunwar Shailubhai as Chief Executive Officer.\n \n\nThis Smart News Release features multimedia. View the full release here: \nhttp://www.businesswire.com/news/home/20170420006678/en/\n\n \n \n Dr. Kunwar Shailubhai, CEO of Rasna Therapeutics, Inc. (Photo: Business Wire) \n\n\n \n “We are delighted to welcome Kunwar into this role,” said Dr. Alessandro \n Padova, Chairman of Rasna Therapeutics, “He brings more than 25 years of \n experience within the life science industry, combined with a \n distinguished track record of success in translating drugs from concept \n through commercialization to market.”\n \n \n “Rasna’s focus on addressing the high unmet need that exists is a \n pressing challenge, with more than ten thousand deaths annually in the \n United States from acute myeloid leukemia,” commented Dr. Shailubhai, “I \n look forward to taking on this challenge and progressing the powerful \n therapeutic approaches that Rasna has developed, which engage novel \n understanding of key mechanisms at the heart of disease biology.”\n \n \n Dr. Shailubhai, who was formally appointed on April 14th, was \n a co-founder and served as the Chief Scientific Officer and prior Senior \n Vice President, Drug Discovery, of Synergy Pharmaceuticals Inc. \n (NASDAQ:SGYP) from 2004, where he led the development of Trulance™ from \n inception to FDA approval, having co-invented and pioneered Synergy’s \n platform technology surrounding the therapeutic applications of \n guanylate cyclase C agonists for functional GI disorders, inflammatory \n bowel disease, GI cancer, cholesterol lowering, asthma and other lung \n diseases.\n \n \n Between 1993 and 2000, he was with Monsanto Company, serving as Research \n Specialist and Group Leader of the cancer chemoprevention group. Dr. \n Shailubhai previously served as a Senior Staff Fellow at the National \n Institutes of Health, and as an Assistant Professor of Research at the \n University of Maryland.\n \n \n Dr. Shailubhai received his Ph.D. in microbiology from the University of \n Baroda, India, and his MBA from the University of Missouri, St. Louis. \n He has more than 20 issued patents and over 40 peer-reviewed \n publications.\n \n \n Abo...